Storys zum Thema Medizin, Gesundheit
-
Sprache:
Englisch
- Medien:
- Zeitraum:
- Zeitraum:Gesamt
- 2mehr
Grünenthal licenses exclusive South Korean rights to Qutenza® to BCWorld Pharm
Aachen, Germany & Yeoju, South Korea (ots) - Grünenthal, a global leader in pain management and related diseases, and BCWorld Pharm Co., Ltd. ("BCWP"), a specialty company actively expanding and diversifying its pain management portfolio through global open innovation partnerships, announced today that they have entered into a definitive agreement whereby BCWP will ...
mehrGrünenthal takes full ownership of Grünenthal Meds, the joint venture established with Kyowa Kirin for its established medicines brands
Aachen, Germany (ots) - - Grünenthal acquired Kyowa Kirin International's 49% stake in 'Grünenthal Meds', a joint venture formed in 2023 to market the established medicines portfolio from Kyowa Kirin International. - Through this acquisition, Grünenthal assumes the sole responsibility of a portfolio comprising 12 ...
mehrSchweizerischer Nationalfonds / Fonds national suisse
Women with severe burn injuries are more likely than men to develop blood poisoning
Bern (ots) - Bacteria in the bloodstream can result in life-threatening complications for burn victims. Women are more susceptible to this than men, according to the unexpected results of a study funded by the SNSF. The skin forms a natural barrier that prevents bacteria entering the body. Severe burns stop this pro-tective function from working properly, and germs can ...
mehrGrünenthal licenses exclusive Australian rights to Qutenza® to Clinect
Aachen, Germany & Victoria, Australia (ots) - Grünenthal, a global leader in pain management and related diseases, and Clinect Pty Ltd ("Clinect"), an Australian based company focussed on supporting access to unique products, announced today that they have entered into a definitive agreement whereby Clinect will have the exclusive Australian rights to Qutenza®, a ...
mehrGrünenthal’s proprietary NaV 1.8 inhibitor enters clinical development
Aachen, Germany (ots) - Grünenthal announced today that the first healthy volunteers have been enrolled in a Phase I trial of its voltage-gated sodium channel (NaV) 1.8 inhibitor. The orally administered investigational medicine aims to provide a non-opioid therapy option across a range of acute and chronic pain conditions. Full results of the trial are expected in ...
mehr
High blood pressure: trained laypeople improve healthcare in rural Africa
mehrSchweizerischer Nationalfonds / Fonds national suisse
"Developing antibiotics is not profitable, hence the crucial role of universities."
mehrAcousia Announces Completion of Patient Enrollment in Phase 2 PROHEAR Study Evaluating ACOU085 (INN: Bimokalner) for the Prevention of Cisplatin-Induced Ototoxicity
Tübingen, Germany (ots) - Acousia Therapeutics GmbH, a clinical-stage biotechnology company developing treatments for acute and chronic inner ear hearing loss, announced the completion of patient enrollment in its Phase 2 PROHEAR clinical study. ACOU085 (INN: Bimokalner) is a proprietary, first-in-class small ...
mehrEuro Airport Basel-Mulhouse-Freiburg
Significantly fewer take-offs after 23:00 at EuroAirport – measures are proving effective
Ein DokumentmehrEuropean Society for Medical Oncology (ESMO)
ESMO releases first-ever guidance for safe use of AI Language Models in cancer care
mehrFemmeHealth Alliance (FHA) launches to bridge Europe’s women’s health innovation gap
mehr
Health is a Political Choice: Global Leaders Call for Shared Responsibility at the World Health Summit, Gallup and GPMB Release Landmark Reports on Emotional Wellbeing and Pandemic Preparedness
mehrServier acquires potential treatment for Fragile X syndrome, the most common genetic cause of autism spectrum disorder
Suresnes, France (ots/PRNewswire) - - Servier acquires KER-0193, a potential treatment for Fragile X syndrome, developed by Kaerus Bioscience, a Medicxi company - KER-0193, a novel, orally bioavailable small molecule, was granted Orphan Drug Designation and Rare Pediatric Drug Designation by U.S. FDA - Acquisition ...
mehrAsklepios Kliniken GmbH & Co. KGaA
Nominations for the Broermann Medical Innovation Award 2026 now open
Hamburg (ots) - - With a million euros, it is one of the world’s most highly endowed awards for medical research The nomination period for the Broermann Medical Innovation Award 2026 has begun. Endowed with a million euros, this international award is among the most prestigious honors for medical research worldwide. Scientists from around the globe who have made ...
mehrGrünenthal PRO is joining SHL Medical’s alliance partnership network to offer final assembly service for Molly® autoinjectors
Aachen (ots) - Grünenthal PRO, the contract development and manufacturing organization (CDMO) division of Grünenthal offering a range of services including final assembly of autoinjectors, is entering into a non-exclusive partnership with SHL Medical, a world-leading solutions provider of advanced drug delivery ...
mehrswissstaffing - Verband der Personaldienstleister der Schweiz
Temporary nursing staff even helping to reduce hospital costs
2 DokumentemehrUCB presents latest research and clinical advancement across leading epilepsy portfolio at International Epilepsy Congress
Brussels (ots/PRNewswire) - - 26 scientific abstracts, including two oral presentations, demonstrate UCB's ongoing commitment to advancing research for people living with epilepsies - Data include an open-label extension study describing the long-term safety of FINTEPLA®▼ (fenfluramine)[1] and global functioning ...
mehr
Schweizerischer Nationalfonds / Fonds national suisse
Getting a grip on pointless antibiotics prescriptions
Bern (ots) - Patients often push their doctors to prescribe antibiotics unnecessarily, increasing bacterial resistance. More trust in patients could help here. This is the surprising outcome of a study supported by the SNSF. Five million people die each year from bacterial infections because the pathogens are resistant to anti-biotics. According to the World Health Organisation (WHO), this figure will double by 2050. ...
mehrSchweizerischer Nationalfonds / Fonds national suisse
More and more children are allergic to cashew nuts
Bern (ots) - Nuts account for around a quarter of all food allergies. Recently, cashew nuts have been causing a particularly high number of severe reactions in children. This is probably because of increased consumption. Whether as a savoury snack or disguised in gluten-free flour and vegan milk, cashew nuts, which originally come from Brazil, are very much in demand. They are rich in protein but contain less fat and ...
mehrMikrona Group Acquires FTC Dental
Baar, Switzerland (ots/PRNewswire) - Mikrona Group AG, a leading Swiss provider of solutions for orthodontics and digital dentistry, has acquired FTC Frey Trading & Consulting Sàrl and its affiliated training platform, MYDENTALEXPERT Sàrl. Mikrona Group is part of Healthcare Holding Schweiz AG, which is managed by Winterberg Advisory and KKA Partners. Healthcare Holding Schweiz AG, through its subsidiary Mikrona Group AG, has completed the acquisition of FTC Frey Trading & ...
mehrCroma-Pharma GmbH Announces Strategic Milestone as Novaestiq Corp. Joins Waldencast
Leobendorf, Austria (ots/PRNewswire) - Saypha® injectables to launch in the U.S. under the Obagi Medical brand, expanding global reach of Croma's science-driven aesthetic solutions Croma-Pharma GmbH, a global leader in minimally invasive aesthetic medicine, today announced the acquisition of Novaestiq Corp. by Waldencast plc (Nasdaq: WALD). Novaestiq, a joint venture ...
mehrABDA Bundesvgg. Dt. Apothekerverbände
Germany’s pharmacies under pressure: Statistical Yearbook 2025 now available
Berlin (ots) - ABDA – Federal Union of German Associations of Pharmacists has released the Statistical Yearbook “German Pharmacies: Figures, Data, Facts 2025”. The publication offers a comprehensive overview of the latest trends in the pharmaceutical and healthcare sectors in Germany and beyond. It shows that the number of pharmacies has decreased again. At the ...
mehrGroupement Hospitalier Loos Haubourdin confirms its partnership with Intalio and Officially Adopts the Intalio Assure Digital Solution
Paris (ots/PRNewswire) - After two years of co-development marked by close collaboration, Groupement Hospitalier Loos Haubourdin (GHLH) has renewed its trust in Intalio, a recognized leader in digital transformation for organizations, by officially adopting the Intalio Assure solution, the digital version of the ...
mehr
Schweizerischer Nationalfonds / Fonds national suisse
Tackling antibiotic resistance by capturing bacteria
Bern (ots) - Rapidly identifying certain bacteria allows antibiotic treatments to be optimised. A team from the University of Zurich, supported by the SNSF, has developed molecules to detect and capture certain species. The discovery of antibiotics revolutionised medicine in the 20th century, saving countless lives. However, the emergence of resistant bacteria has quickly become a new challenge. One key factor in tackling ...
mehrMedison Expands Global Leadership Team with Chief Business Officer and Chief Legal & Compliance Officer
Petach Tikva, Israel (ots/PRNewswire) - Strategic appointments reflect Medison's continued investment in global scale and operational excellence Medison, the creator of a first-of-its-kind unified global commercialization platform that accelerates the launch of breakthrough therapies in markets beyond the U.S., ...
mehrIsomorphic Labs appoints Dr. Ben Wolf as Chief Medical Officer and establishes US Presence
London and Boston (ots/PRNewswire) - Precision oncology leader joins world-class team as company enters next phase of translating AI-driven drug discovery into life-changing medicines. Isomorphic Labs, the AI-first drug discovery company, has announced the appointment of Ben B. Wolf, M.D., Ph.D., as Chief Medical Officer. Dr. Wolf will be based in the company's newly ...
mehrMedHub-AI and Terumo partner to market AI-based FFR in Japan
Tel Aviv, Israel (ots/PRNewswire) - MedHub-AI, pioneer of AI-based FFR "AutocathFFR" software, today announced a distribution agreement with Terumo Corporation to bring AutocathFFR®, its groundbreaking AI-powered Software as a Medical Device (SaMD), to the Japanese market. This partnership marks a new era in coronary physiology assessment where AI technology delivers superior confidence, reproducibility, and clinical ...
mehrInnovative Molecules Completes Enrollment of Phase 1b Clinical Trial of IM-250
Munich (ots/PRNewswire) - Innovative Molecules GmbH Announces Completion of Phase 1b Enrollment for IM-250 in Genital Herpes Clinical Trial Innovative Molecules GmbH today announced the completion of enrollment in the Phase 1b portion of its ongoing Phase 1b/2a clinical trial evaluating IM-250, a next-generation helicase-primase inhibitor targeting herpes simplex virus ...
mehrEidgenössisches Nuklearsicherheitsinspektorat ENSI
Radiation Protection Report 2024: All Legal Limits Met
Brugg (ots) - Swiss nuclear installations met all legal radiation protection limits according to ENSI's Radiation Protection Report 2024. Nuclear installation operators have implemented legally compliant and appropriate radiation protection during all operating phases. ENSI also did not detect any increase in local dose rates in the vicinity that could be traced back to emissions from the nuclear installations. Personal ...
mehr